88 related articles for article (PubMed ID: 226020)
1. Comparison of the inhibitory effects of acetylsalicylic acid and trifusal on enzymes related to thrombosis.
Garcia Rafanell J; Planas JM; Puig-Parellada P
Arch Int Pharmacodyn Ther; 1979 Feb; 237(2):343-50. PubMed ID: 226020
[TBL] [Abstract][Full Text] [Related]
2. Reversible inhibition of thromboxane A2 production by imidazole 2-hydroxybenzoate (ITF 182) in the arachidonic acid injected rat. A comparison with acetylsalicylic acid and indometacin.
Pagella PG; Agozzino S; Bellavite O; Donà GC
Arzneimittelforschung; 1984; 34(5):597-8. PubMed ID: 6432000
[TBL] [Abstract][Full Text] [Related]
3. Effects of a thromboxane synthetase inhibitor and a cAMP phosphodiesterase inhibitor, singly and in combination, on platelet behaviour.
Sills T; Heptinstall S
Thromb Haemost; 1986 Jun; 55(3):305-8. PubMed ID: 3018954
[TBL] [Abstract][Full Text] [Related]
4. [Pharmacology of anti-platelet agents].
Lecompte T; Kher A; Gaillard JL; Samama M
J Mal Vasc; 1983; 8(1):3-16. PubMed ID: 6302191
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological characterization of FCE 27262, a combined thromboxane synthase inhibitor and PGH2/TXA2 receptor antagonist.
Vaghi F; Colombo M; Pierucci L; Volpi D; Dho L; Ukmar G; Rosa B; Salvati P
Drugs Exp Clin Res; 1993; 19(6):249-60. PubMed ID: 8013268
[TBL] [Abstract][Full Text] [Related]
6. The effect of a thromboxane synthetase inhibitor, dazoxiben, and acetylsalicylic acid on platelet function and prostaglandin metabolism.
Dale J; Thaulow E; Myhre E; Parry J
Thromb Haemost; 1983 Oct; 50(3):703-6. PubMed ID: 6689091
[TBL] [Abstract][Full Text] [Related]
7. A thromboxane A2/prostaglandin H2 receptor antagonist (S18886) shows high antithrombotic efficacy in an experimental model of stent-induced thrombosis.
Vilahur G; Casaní L; Badimon L
Thromb Haemost; 2007 Sep; 98(3):662-9. PubMed ID: 17849057
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological manipulation of canine cyclooxygenase and thromboxane synthetase in vivo: differential renal and platelet recovery rates.
Oshima T; McCluskey ER; Honda A; Needleman P
J Pharmacol Exp Ther; 1984 May; 229(2):598-602. PubMed ID: 6425495
[TBL] [Abstract][Full Text] [Related]
9. Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis.
Schrör K
Semin Thromb Hemost; 1997; 23(4):349-56. PubMed ID: 9263351
[TBL] [Abstract][Full Text] [Related]
10. [Pharmacologic and dietary management of prostaglandin synthesis in the prevention of thrombosis].
Carreras LO
Sangre (Barc); 1982; 27(2):198-217. PubMed ID: 6289481
[No Abstract] [Full Text] [Related]
11. Comparison of in vitro effects of triflusal and acetysalicylic acid on nitric oxide synthesis by human neutrophils.
Sánchez de Miguel L; Casado S; Farré J; García-Durán M; Rico LA; Montón M; Romero J; Bellver T; Sierra MP; Guerra JI; Mata P; Esteban A; López-Farré A
Eur J Pharmacol; 1998 Feb; 343(1):57-65. PubMed ID: 9551715
[TBL] [Abstract][Full Text] [Related]
12. 7-Bromo-1,5-dihydro-3,6-dimethylimidazo[2,1-b]quinazolin-2(3H)- one (Ro 15-2041), a potent antithrombotic agent that selectively inhibits platelet cyclic AMP-phosphodiesterase.
Muggli R; Tschopp TB; Mittelholzer E; Baumgartner HR
J Pharmacol Exp Ther; 1985 Oct; 235(1):212-9. PubMed ID: 2995647
[TBL] [Abstract][Full Text] [Related]
13. Protective effects of triflusal on secondary thrombus growth and vascular cyclooxygenase-2.
Duran X; Sánchez S; Vilahur G; Badimon L
J Thromb Haemost; 2008 Aug; 6(8):1385-92. PubMed ID: 18503633
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of cyclooxygenase-2 expression by 4-trifluoromethyl derivatives of salicylate, triflusal, and its deacetylated metabolite, 2-hydroxy-4-trifluoromethylbenzoic acid.
Fernández de Arriba A; Cavalcanti F; Miralles A; Bayón Y; Alonso A; Merlos M; García-Rafanell J; Forn J
Mol Pharmacol; 1999 Apr; 55(4):753-60. PubMed ID: 10101034
[TBL] [Abstract][Full Text] [Related]
15. [Comparative study of the antithrombotic effect of aspirin and Bay U3405, antagonist of a thromboxane A2 receptor].
Cissé-Thiam M; Drouet L
Dakar Med; 1999; 44(1):25-7. PubMed ID: 10797981
[TBL] [Abstract][Full Text] [Related]
16. Protective effect of triflusal and its main metabolite HTB in an in vitro model of anoxia-reoxygenation in rat brain slices: comparison with acetylsalicylic and salicylic acids.
González-Correa JA; Arrebola MM; Ureña IM; Ruiz-Villafranca D; Muñoz-Marín J; Guerrero A; Sánchez de la Cuesta F; De La Cruz JP
Naunyn Schmiedebergs Arch Pharmacol; 2005 Jan; 371(1):81-8. PubMed ID: 15602657
[TBL] [Abstract][Full Text] [Related]
17. Endogenous prostacyclin contributes to the efficacy of a thromboxane synthetase inhibitor for preventing coronary artery thrombosis.
Aiken JW; Shebuski RJ; Miller OV; Gorman RR
J Pharmacol Exp Ther; 1981 Nov; 219(2):299-308. PubMed ID: 6270303
[No Abstract] [Full Text] [Related]
18. Synergistic antiplatelet effect of ridogrel, a combined thromboxane receptor antagonist and thromboxane synthase inhibitor, and UDCG-212, a cAMP-phosphodiesterase inhibitor.
Hoet B; Arnout J; Deckmyn H; Vermylen J
Thromb Haemost; 1993 Nov; 70(5):822-5. PubMed ID: 8128441
[TBL] [Abstract][Full Text] [Related]
19. Effect of triflusal and acetylsalicylic acid on platelet aggregation in human whole blood: influence of red blood cells and leukocytes.
de la Cruz JP; Pavia J; Bellido I; Sánchez de la Cuesta F
Methods Find Exp Clin Pharmacol; 1988 Jun; 10(6):363-7. PubMed ID: 3412046
[TBL] [Abstract][Full Text] [Related]
20. Effect of triflusal and other salicylic acid derivatives on cyclic AMP levels in rat platelets.
García-Rafanell J; Ramis J; Gomez L; Forn J
Arch Int Pharmacodyn Ther; 1986 Nov; 284(1):155-65. PubMed ID: 3030206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]